Company Overview of Enzo Life Sciences, Inc.
Enzo Life Sciences, Inc. researches, develops, manufactures, licenses, and markets life science research reagents. It offers proteins, antibodies, peptides, small molecules, labeling probes dyes, ELISA kits, natural products, neurochemicals, enzymes, and inhibitors to provide life science researchers tools for target identification/validation, high content and gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. The company also provides DNA, RNA, and protein quantification assays; genomics and general molecular biology tools; molecular labels and probes; compound libraries; and enzymatic, protein, and immunological assays. In addition,...
10 Executive Boulevard
Farmingdale, NY 11735
Founded in 1976
Key Executives for Enzo Life Sciences, Inc.
President of Enzo Biochem Inc
Head of Global Technology Business Development
Compensation as of Fiscal Year 2014.
Enzo Life Sciences, Inc. Key Developments
Enzo Biochem Announces Settlement Agreement with PerkinElmer
Jun 23 14
Enzo Biochem, Inc. along with its subsidiary Enzo Life Sciences, Inc. entered into a Settlement with PerkinElmer, Inc. and PerkinElmer Health Sciences, Inc. with respect to an action between the Company and PerkinElmer before the U.S. District Court, Southern District of New York, Case No 03-CV-3817. PerkinElmer, Inc. has agreed to pay $7,000,000 in escrow in settlement pursuant to the Agreement.
Andrew Whiteley Resigns as Chief Operating Officer for Enzo Life Sciences
May 29 14
Enzo Biochem Inc. announced that Andrew Whiteley is no longer with the company in the role as Chief Operating Officer for Enzo Life Sciences.
Enzo Life Sciences, Inc. Announces Earnings Results for the First Quarter of Fiscal Year 2013
Dec 11 12
Enzo Life Sciences, Inc. announced earnings results for the first quarter of fiscal year 2013. For the quarter, the company reported operating income of $1.4 million. This was an increase of $1.6 million over a year ago when it lost $200,000. The gains at Life Sciences were achieved despite a 13% decline in revenues, reflecting its program to consolidate facilities and functions and implement operational efficiencies, as well as concentrating on marketing efforts towards a more value-added mix of products. In line with the product rationalization program emphasizing fewer but higher-margin products, net revenues declined 13% to $8.4 million.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|